Bruna B. Rocha

Bruna Rocha specializes in providing comprehensive counsel to a diverse clientele in the life sciences and healthcare sector, including pharmaceutical companies, clinical research organizations, biotechs, digital health providers, and cannabis companies. With a focus on transactional and regulatory matters, Bruna collaborates closely with C-level executives, investors, developers, managers, and physicians, guiding them through every facet of their legal activities. Her expertise encompasses a broad spectrum, ranging from assisting in business formation and establishing investment platforms for companies entering new markets to facilitating cross-border portfolio acquisitions and restructuring initiatives. Bruna's commitment extends to advising companies on medical therapies across the entire laboratory-to-market process.

Bruna also provides strategic guidance on forging business alliances, negotiating commercial contracts, and navigating regulatory landscapes. She is well-versed in addressing reputational risks associated with product liability and safety concerns, as well as staying at the forefront of technological innovation. Bruna's insights cover diverse areas, including the integration of artificial intelligence in healthcare, mobile medical applications, health information exchange, the Internet of Medical Things (IoMT), wearable devices, and bio printing.

Bruna Rocha's legal acumen and strategic counsel play a pivotal role in steering her clients through the intricacies of the ever-evolving landscape of pharmaceuticals, healthcare, and emerging technologies.

DLA Piper and Campos Mello Advogados (CMA) are separate and independent law firms, which work in cooperation with one another. Partners of DLA Piper are not partners of CMA; and CMA partners are not partners of DLA Piper.